The IDIS database consists of full-text articles and an index of article citations selected from 200 peer-reviewed English language journals. The database is sold on a subscription basis. Full-text articles are available on microfiche, CD-ROM and the web.

 

 

IDIS Training Tools

 

Stay Connected:

 • IDIS on Facebook

 • Join Our Update Lists

 • CAMIPR

 • Monthly Update Information

 

 

Email: idis@uiowa.edu



Notice: IDIS database discontinuation December 31, 2014.   Read more.

IDIS Logo   Iowa Drug Information Service

Drug Information Database

Articles and reports for the IDIS database are selected from 200 peer-reviewed English language medical and pharmaceutical journals, FDA approval packages, FDA Advisory Committee briefing documents, FDA boxed warnings, AHRQ publications, National Institute for Health and Clinical Excellence (NICE) guidelines and appraisals, clinical practice guidelines and more.

Among the areas covered are pharmacy and pharmacology, general and internal medicine, infectious disease and immunology, transplant, cardiovascular, rheumatology, microbiology, geriatrics, and endocrinology. For a complete listing of the journals indexed by IDIS, go to the Journal List (by category or alphabetical).

IDIS pharmacists index those articles that pertain to drug use in humans, identifying the main drugs and diseases. Descriptors, such as type of article, routes of administration, side effects and pharmacokinetics, are used to help specify information contained in each article, facilitating easy retrieval of relevant articles. For a complete listing of the descriptors, go to the Descriptor List.

IDIS has been indexing the U.S. Food and Drug Administration's (FDA) Approval Packages [formerly known as Summary Basis of Approval Equivalents (SBA)] since 1998. These contain key studies which have been submitted to the FDA by the pharmaceutical manufacturers.

IDIS publishes a quarterly newsletter, World of Drug Information, which contains a timely clinical topic with ACPE continuing education credit available. The newsletter also includes regular features such as new FDA drug/biologic approvals, and occasionally, articles contributed by subscribers.


College of Pharmacy